Neurocrine Biosciences (NBIX) : Nexthera Capital Lp scooped up 15,000 additional shares in Neurocrine Biosciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 42,000 shares of Neurocrine Biosciences which is valued at $2,031,960.Neurocrine Biosciences makes up approximately 1.99% of Nexthera Capital Lp’s portfolio.
Other Hedge Funds, Including , Cubist Systematic Strategies boosted its stake in NBIX in the latest quarter, The investment management firm added 42,539 additional shares and now holds a total of 48,245 shares of Neurocrine Biosciences which is valued at $2,334,093. Neurocrine Biosciences makes up approx 0.12% of Cubist Systematic Strategies’s portfolio.Callan Capital reduced its stake in NBIX by selling 7,000 shares or 31.82% in the most recent quarter. The Hedge Fund company now holds 15,000 shares of NBIX which is valued at $725,700. Neurocrine Biosciences makes up approx 0.28% of Callan Capital’s portfolio. Omers Administration Corp added NBIX to its portfolio by purchasing 39,000 company shares during the most recent quarter which is valued at $1,886,820. Neurocrine Biosciences makes up approx 0.04% of Omers Administration Corp’s portfolio.Blackrock Institutional Trust Company N.a. reduced its stake in NBIX by selling 16,995 shares or 0.84% in the most recent quarter. The Hedge Fund company now holds 2,014,672 shares of NBIX which is valued at $97,469,831. Neurocrine Biosciences makes up approx 0.02% of Blackrock Institutional Trust Company N.a.’s portfolio.Fortaleza Asset Management Inc reduced its stake in NBIX by selling 1,620 shares or 33.75% in the most recent quarter. The Hedge Fund company now holds 3,180 shares of NBIX which is valued at $158,905. Neurocrine Biosciences makes up approx 0.12% of Fortaleza Asset Management Inc’s portfolio.
Neurocrine Biosciences opened for trading at $48.63 and hit $50.28 on the upside on Thursday, eventually ending the session at $50.12, with a gain of 3.43% or 1.66 points. The heightened volatility saw the trading volume jump to 5,68,942 shares. Company has a market cap of $4,348 M.
On the company’s financial health, Neurocrine Biosciences reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.49.During the same quarter in the previous year, the company posted $-0.28 EPS.
Many Wall Street Analysts have commented on Neurocrine Biosciences. H.C. Wainwright Initiated Neurocrine Biosciences on Jun 29, 2016 to “Buy”, Price Target of the shares are set at $80.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.